SYA dark blue font on white background (1).jpg
Syapse Enters Collaboration with Merck Using Real-World Evidence to Better Understand Cancers
15 sept. 2022 08h00 HE | Syapse
SAN FRANCISCO and NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing...
SYA dark blue font on white background (1).jpg
Syapse and Genesis Research Combine Forces to Offer Real-World Evidence Services and Data to Oncology Innovators
31 août 2022 08h00 HE | Syapse
SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
SYA dark blue font on white background (1).jpg
Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network
27 juil. 2022 09h00 HE | Syapse
SAN FRANCISCO and NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing...
SYA dark blue font on white background (1).jpg
Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology
14 juin 2022 10h00 HE | Syapse
SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company announced with Pierian®, a global leader in advanced clinical genomics technology, a new joint...
SYA dark blue font on white background (1).jpg
Syapse Unveils Two New Studies on Use of Machine Learning on Real-World Data to Identify and Treat Cancer With Precision at ASCO 2022
27 mai 2022 10h00 HE | Syapse
SAN FRANCISCO, May 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
SYA dark blue font on white background (1).jpg
Syapse Announces Changes to Board of Directors, Adding Michael Mentesana and Elevating Frank Williams to Chairman Role
31 mars 2022 10h00 HE | Syapse
SAN FRANCISCO, March 31, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
SYA dark blue font on white background (1).jpg
Main Line Health Collaborates with Syapse, Bringing Clinical Trial Opportunities to Patients with Cancer in Philadelphia Region
22 mars 2022 10h00 HE | Syapse
SAN FRANCISCO, March 22, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
SYA dark blue font on white background (1).jpg
Syapse Extends Collaboration with Pfizer to Continue to Generate Real-World Evidence in Breast Cancer
20 janv. 2022 10h00 HE | Syapse
SAN FRANCISCO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
SYA dark blue font on white background (1).png
Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices
04 janv. 2022 09h00 HE | Syapse
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
SYA dark blue font on white background (1).png
Syapse Recognized by Comparably Awards Across Four Categories
17 déc. 2021 10h00 HE | Syapse
SAN FRANCISCO, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...